![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Publisher's version)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
| Item Type: | Review |
|---|---|
| Title: | Refining AML treatment: the role of genetics in response and resistance evaluation to new agents |
| Creators Name: | Halik, A., Arends, C.M., Bullinger, L., Damm, F. and Frick, M. |
| Abstract: | The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351. |
| Keywords: | AML, Mutations, FLT3, IDH1/2, Venetoclax, Gemtuzumabozogamicin, CPX-351, Targeted Therapy, Precision Medicine |
| Source: | Cancers |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Volume: | 14 |
| Number: | 7 |
| Page Range: | 1689 |
| Date: | 26 March 2022 |
| Official Publication: | https://doi.org/10.3390/cancers14071689 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
